Lilly Endowment Inc
- SEC CIK
- 0000316011
- Latest filing
- Jul 23, 2026
The latest 13F from Lilly Endowment Inc covers Q2 2026 (filed Jul 23, 2026): 1 long positions worth $108.4B. The top 10 holdings make up 100.0% of the portfolio, and the largest is Eli Lilly & Co (LLY) at 100.0%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 1
- Est. −$1.82B
- Sold out
- 0
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $108.4B
- +$23.9B (+28.2%) vs. prior quarter
- Positions
- 1
- 0 vs. prior quarter
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- 0.0%
- Q2 2026, one quarter
- Average holding period
- 22.0 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $108.4B (Q2 2026)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | 1 | $108.4B | LLY | vs. Q1 2026 | SEC |
| Q1 2026 | Apr 20, 2026 | 1 | $84.5B | LLY | vs. Q4 2025 | SEC |
| Q4 2025 | Jan 23, 2026 | 1 | $99.1B | LLY | vs. Q3 2025 | SEC |
| Q3 2025 | Oct 31, 2025 | 1 | $72.9B | LLY | vs. Q2 2025 | SEC |
| Q2 2025 | Jul 10, 2025 | 1 | $74.8B | LLY | vs. Q1 2025 | SEC |
| Q1 2025 | Apr 16, 2025 | 1 | $79.3B | LLY | vs. Q4 2024 | SEC |
| Q4 2024 | Jan 27, 2025 | 1 | $74.8B | LLY | vs. Q3 2024 | SEC |
| Q3 2024 | Oct 3, 2024 | 1 | $85.8B | LLY | vs. Q2 2024 | SEC |
| Q2 2024 | Jul 16, 2024 | 1 | $88.2B | LLY | vs. Q1 2024 | SEC |
| Q1 2024 | Apr 16, 2024 | 1 | $76.9B | LLY | vs. Q4 2023 | SEC |
| Q4 2023 | Jan 25, 2024 | 1 | $58.2B | LLY | vs. Q3 2023 | SEC |
| Q3 2023 | Oct 12, 2023 | 1 | $53.7B | LLY | vs. Q2 2023 | SEC |
| Q2 2023 | Jul 10, 2023 | 1 | $47.4B | LLY | vs. Q1 2023 | SEC |
| Q1 2023 | Apr 17, 2023 | 1 | $35.2B | LLY | vs. Q4 2022 | SEC |
| Q4 2022 | Jan 26, 2023 | 1 | $37.7B | LLY | vs. Q3 2022 | SEC |
| Q3 2022 | Oct 5, 2022 | 1 | $33.6B | LLY | vs. Q2 2022 | SEC |
| Q2 2022 | Jul 18, 2022 | 1 | $33.8B | LLY | vs. Q1 2022 | SEC |
| Q1 2022 | Apr 19, 2022 | 1 | $30.4B | LLY | vs. Q4 2021 | SEC |
| Q4 2021 | Jan 27, 2022 | 1 | $29.7B | LLY | vs. Q3 2021 | SEC |
| Q3 2021 | Oct 8, 2021 | 1 | $25.0B | LLY | vs. Q2 2021 | SEC |
| Q2 2021 | Jul 19, 2021 | 1 | $25.1B | LLY | vs. Q1 2021 | SEC |
| Q1 2021 | Apr 12, 2021 | 1 | $20.6B | LLY | – | SEC |
13D and 13G filings
Companies where Lilly Endowment Inc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
1 company, largest stake first.
Latest filings
11 filings on file made by Lilly Endowment Inc or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| LLYEli Lilly & Co | Jul 23, 202610:12 AM ET | 13G/A | 9.60%90.4M shares | −0.10 ppfrom 9.70% | Jun 30, 2026 | SEC |
| LLYEli Lilly & Co | Apr 20, 20263:25 PM ET | 13G/A | 9.70%91.9M shares | −0.10 ppfrom 9.80% | Mar 31, 2026 | SEC |
| LLYEli Lilly & Co | Jan 23, 20269:27 AM ET | 13G/A | 9.80%92.2M shares | −0.30 ppfrom 10.10% | Dec 31, 2025 | SEC |
| LLYEli Lilly & Co | Oct 30, 20255:34 PM ET | 13G/A | 10.10%95.5M shares | 0.00 ppfrom 10.10% | Sep 30, 2025 | SEC |
| LLYEli Lilly & Co | Apr 16, 202511:20 AM ET | 13G/A | 10.10%96.0M shares | −0.10 ppfrom 10.20% | Mar 31, 2025 | SEC |
| LLYEli Lilly & Co | Jan 27, 20253:54 PM ET | 13G/A | 10.20%96.9M shares | – | Dec 31, 2024 | SEC |
| LLYEli Lilly & Co | Oct 23, 2024 | 13G/AOld format | – | – | – | SEC |
| LLYEli Lilly & Co | Jan 26, 2024 | 13G/AOld format | – | – | – | SEC |
| LLYEli Lilly & Co | Jan 25, 2023 | 13G/AOld format | – | – | – | SEC |
| LLYEli Lilly & Co | Jan 27, 2022 | 13G/AOld format | – | – | – | SEC |
| LLYEli Lilly & Co | Jan 21, 2021 | 13G/AOld format | – | – | – | SEC |